The company sticks with EZH2, despite others adding EZH1 inhibition.

Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.

Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.

MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.

Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.

Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.

Pelabresib’s Manifest-2 trial yields mixed data, but the bad part could render the whole unpalatable.